C9orf72 and Splenomegaly: Remarkably, splenomegaly and lymphadenopathy in C9orf72−/− mice were greatly reduced after 2 weeks of ruxolitinib treatment and significantly rescued after 3 weeks of ruxolitinib treatment (Figure 5A).